Background: Obesity and the metabolic syndrome have emerged as clinical and public health crises in many populations, but not all obese patients have the syndrome. As adipocytes produce several adipokines that modulate insulin action as well as glucose and lipid metabolism, we postulate that estimation of adipokines may be useful addition to the criteria used to identify obese individuals with the metabolic syndrome. Objective: To evaluate the determinants and associations of plasma adiponectin in relation to the metabolic syndrome in patients with Type 2 diabetes. Design: Cross-sectional study. Setting: General Teaching Hospital. Patients: One hundred and thirty five (57 M, 78 F) patients with Type 2 diabetes mellitus. Measurements: Adiponectin, leptin, high-sensitivity C-reactive protein (hs-CRP), fasting plasma insulin, glucose, glycated hemoglobin and full lipid profile. Patients were classified on the basis of the degree of adiposity, insulin resistance (IR) (homeostasis model assessment of insulin resistance (HOMA-IR)) and the number of the American Heart Association and the National Heart, Lung and Blood Institute criteria of the metabolic syndrome. Results: Adiponectin levels were inversely correlated with age, indices of obesity, IR and hs-CRP. Overweight/obese and nonobese insulin-sensitive patients had significantly higher (Po0.05) adiponectin levels than those with IR despite similar body mass index and waist circumference. Therefore, within each category of obesity stratification, lower adiponectin levels were associated with IR. Adiponectin showed stepwise decrease with increasing number of the criteria for diagnosis of the metabolic syndrome. Using multiple logistic regression, the odds ratio of the metabolic syndrome as predicted by adiponectin was 0.73 (95% confidence interval 0.53-0.96; P ¼ 0.04). At cutoff point of 18 ng/ml, the diagnostic sensitivity and specificity of adiponectin for the metabolic syndrome were 83 and 65%, respectively, in male patients and 92 and 41%, respectively, in female patients. Receiver operating characteristic analysis showed that adiponectin had significantly higher area under the curve compared with leptin, leptin:adiponectin ratio and triglycerides for the detection of the metabolic syndrome. Conclusions: In patients with Type 2 diabetes, adiponectin concentrations are closely related to IR and the components of the metabolic syndrome. Adiponectin concentration may be a useful addition to the criteria used for identifying obese subjects with the metabolic syndrome.
Introduction
Obesity and associated co-morbidities have emerged as clinical and public health crises in many populations. 1, 2 The co-morbidities associated with obesity include a clustering of metabolic derangements including insulin resistance (IR), glucose intolerance, dyslipidemia and hypertension that cluster in the metabolic syndrome. However, not all obese individuals present with these disorders and specific criteria have been defined for the metabolic syndrome. 3 As lifestyle changes, such as dieting, exercise and weight loss, decrease IR and reduce the risk of the metabolic syndrome, early identification of obese patients who are likely to develop the syndrome would be clinically useful.
Recent research has shown that secretory proteins from adipose tissue (adipokines) have an impact on glucose and lipid metabolism and contribute to the pathogenesis of the metabolic syndrome. Adiponectin is the major adipokine secreted by adipose tissue and, in view of the fact that the prevalence of the metabolic syndrome increases in proportion with the degree of obesity, we postulate that adipokines, such as leptin and adiponectin, could be included in the criteria used for the identification of subjects with the syndrome. Therefore, our aim was to evaluate the determinants and associations of leptin and adiponectin in relation to the number of clinical and metabolic abnormalities constituting the metabolic syndrome as defined by the American Heart Association and the National Heart, Lung and Blood Institute (AHA/NHLBI) diagnostic criteria. 3 We also evaluated the performance characteristics of adiponectin, leptin and the leptin:adiponectin ratio as markers for the identification of patients with the metabolic syndrome.
Materials and methods

Patients and clinical features
All patients referred to the specialized diabetes clinic (after diagnosis in primary care clinics) at the Mubarak Al Kabir hospital were eligible to take part in this study. All patients gave informed voluntary consent to participate in the study according to the protocol approved by the local ethics committee and in accordance with the ethical standards of the Helsinki declaration. Exclusion criteria were refusal to take part in the study, inter-current illness or clinically evident infections and treatment with insulin or insulinsensitizing drugs (thiazolidinedione compounds). No patient had overt evidence of infection or connective tissue diseases.
(57 M, 78 F; One hundred and thirty-five patients aged 43-80 years) were studied. The weight, height, waist (WC) and hip circumferences were measured using standard methods and the body mass index (BMI) (kg/m 2 ) and waist-to-hip ratio (WHR) were calculated. Subjects were classified as being either overweight/obese or non-obese on the basis of BMI. The BMI cut points chosen to make this distinction were values of X25.0 or o25.0 kg/m 2 , respectively. Systolic and diastolic blood pressures were measured and hypertension was defined as systolic blood pressure X140 mm Hg or diastolic blood pressure X90 mm Hg or hypertension diagnosed by a physician with prescription and use of antihypertensive medication. 4 Information on patients smoking status was obtained from their responses to a questionnaire. Patients were classified into those with coronary heart disease (CHD) and without CHD based on the symptoms of cardiovascular disease, previous myocardial infarction or angina as well as electrocardiographic abnormalities compatible with CHD. 5, 6 Laboratory methods Adiponectin assay. Fasting plasma adiponectin was measured using a commercially available enzyme-linked immunoassay (ELISA) kit (BioVendor, Brno, Czech Republic) with a sensitivity of 0.78 ng/ml. The inter-and intra-assay coefficients of variation on pooled plasma specimen with adiponectin concentration of 16.4 ng/ml were 4.7 and 6.8%, respectively.
Leptin assay. Plasma leptin concentration was determined with the WAK ELISA kit (Diagnostics Systems Laboratories, Webster, TX, USA), which has an assay sensitivity of 0.05 ng/ml. The inter-and intra-assay coefficients of variation on pooled plasma specimen with leptin concentration of 23.6 ng/ml were 4.1 and 5.3%, respectively.
Other laboratory methods. Fasting serum insulin was determined by an ELISA (DSL-10-1600 ACTIVE, Diagnostics Systems Laboratories, TX, USA). Insulin resistance was calculated using the homeostasis model assessment of insulin resistance (HOMA-IR) formula using a calculator downloaded from http://www.dtu.ox.ac.uk/index.html?maindoc ¼ /publications/. 7 The HOMA calculator also gives estimates of steady-state beta-cell function (%B) and insulin sensitivity (%S). As both glucose and insulin levels are measured, the HOMA calculation has been shown to give good correlation with non-steady-state estimates of beta-cell function and insulin sensitivity derived from stimulatory models such as the hyperinsulinemic clamp. 7 HOMA-IR index 42 was taken to indicate IR. 8 The concentration of C-reactive protein (CRP) was determined by a high-sensitivity (hs) chemiluminescent assay on the Immulite (DPC, Los Angeles, CA, USA). The assay has a lower limit of detection of 0.1 mg/l. The intra-and interassay coefficients of variation for hs-CRP have been reported elsewhere. 9 Fasting plasma glucose (FPG), total cholesterol (TC), triglycerides (TGs), high-density lipoprotein cholesterol (HDL-C), apolipoprotein-A1 (Apo-A1), apolipoprotein-B (Apo B) and creatinine were analyzed on an automated analyzer (Beckman LX20, Beckman Corporation, Brea, CA, USA). The low-density lipoprotein cholesterol (LDL-C) was calculated using the Friedewald formula. 10 Glycated hemoglobin (HbA 1c ) was measured on the Beckman LX20 analyser (Beckman Corporation, Brea, CA, USA). Each patient provided fresh early morning urine samples for the determination of urine microalbumin concentration, which was measured with the Beckman Array analyzer (Beckman Corporation, Brea, CA, USA). Urine creatinine was determined with the Beckman Synchron LX20 automated analyser (Beckman Corporation, Brea, CA, USA). The intra-and inter-assay coefficients of variation for urinary albumin assay have been reported previously. 11 The patients were classified on the basis of the mean urinary albumin: creatinine excretion ratio of three consecutive early morning urine collections as normo-, micro-or macro-albuminuric.
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Adiponectin and the metabolic syndrome OA Mojiminiyi et al were recorded. The patients were then classified as metabolic syndrome positive if they met three or more of the criteria or metabolic syndrome negative if they did not.
Statistical methods SPSS 12.0 software (SPSS Inc., Chicago, IL, USA) was used for statistical analysis and Po0.05 was considered statistically significant for all analyses. Data are presented as median (inter-quartile range), except in error bar plots where the software default option of mean and 95% confidence interval (CI) were used. Spearman's correlation coefficients (r) were used to describe the association between serum adiponectin and other continuous variables of interest; the partial correlation coefficient was used to control for the effects of gender, age and BMI. Comparison between two groups was performed with the Mann-Whitney U-test and the Kruskal-Wallis analysis of variance was used to compare more than two groups. Logistic regression analysis was used to ascertain the association of leptin and adiponectin with the metabolic syndrome as dependent variable. In the logistic regression analyses, we included potential confounding variables such as systolic and diastolic blood pressures, smoking, leptin or adiponectin, hs-CRP, HOMA-IR, %S and levels of FPG, HbA 1c , Apo A1, Apo B, TC, HDL-C, TG and urinary albumin creatinine ratio. To assess the diagnostic accuracy of the adiponectin, leptin, leptin:adiponectin ratio, HDL-C and TG in predicting the metabolic syndrome, receiver operating characteristic (ROC) plots 13 were performed. The area under the curve (AUC) and 95% CI were calculated for each plot and compared by t-test.
Results Table 1 summarizes the characteristics of the patients grouped by gender and the metabolic syndrome status. In general, the patients who are metabolic syndrome positive had more atherogenic lipid profile, were more insulin resistant and had lower adiponectin than patients who were metabolic syndrome negative. However, Table 1 shows that there are differences in the clinical and metabolic expression of the metabolic syndrome in males and females. For example, IR was significantly different in females but not in males. With respect to inflammatory markers, hs-CRP levels were significantly higher in the male patients with the metabolic syndrome only. Unlike adiponectin, leptin was not significantly different when patients with the metabolic syndrome were compared with those who did not have the syndrome. Association of leptin and adiponectin with the number of metabolic syndrome components There was a stepwise decrease in plasma adiponectin levels in parallel to the number of metabolic syndrome components present, and subjects with four or five components of the metabolic syndrome had the lowest adiponectin concentration, but leptin showed the opposite trend (Figure 1) .
Logistic regression analyses showed that the odds ratio (OR) of the metabolic syndrome as predicted by adiponectin in the presence of potential confounding variables (systolic and diastolic blood pressures, smoking, leptin, hs-CRP, HOMA-IR, %S and levels of FPG, HbA 1c , Apo A1, Apo B, TC, HDL-C, TG and urinary albumin creatinine ratio) was 0.73 (95% CI, 0.53-0.96; P ¼ 0.04), indicating that there was a 23% decrease in the odds of having the metabolic syndrome for each 1 ng/ml increase in adiponectin levels, whereas the OR (95% CI) for leptin was 0.87 (0.75-1.01; P ¼ 0.06). However, using the ratio of leptin to adiponectin improved the OR to 8.54 (1.17-32.40; P ¼ 0.03). Table 2 summarizes the Spearman rank correlations between adiponectin, leptin and components of the metabolic syndrome and other metabolic variables in all patients. Table 2 shows that plasma adiponectin was inversely correlated with measures of obesity, insulin and HOMA-IR. Furthermore, adiponectin was inversely correlated with hs-CRP but not with leptin. Adiponectin did not show significant (P40.05) correlation with serum creatinine (r ¼ 0.01) and the urine microalbumin:creatinine ratio (r ¼ À0.10), suggesting that diabetic nephropathy is probably not a significant determinant of adiponectin in our cohort. This is at variance with a previous report, which found that renal function and degree of nephropathy are significant determinants of adiponectin.
Correlations of leptin and adiponectin
14 Table 3 shows that after correcting for the effects of gender, age and BMI, the only variables that showed significant partial correlations with adiponectin were WC, Apo B and leptin:adiponectin ratio, suggesting that these are the only variables whose associations with adiponectin are independent of age, gender and BMI.
Leptin and adiponectin in relation to insulin resistance Figure 2 shows the trend of adiponectin and leptin in patients with varying degrees of obesity and IR. Overweight/ Adiponectin and the metabolic syndrome OA Mojiminiyi et al obese (P ¼ 0.03) and non-obese (P ¼ 0.04) insulin-sensitive patients had significantly higher adiponectin levels than those with IR patients despite similar BMI and WC. Therefore, within each category of obesity stratification, lower adiponectin levels were associated with IR. In contrast, leptin was significantly higher in overweight/obese (P ¼ 0.001) and non-obese (P ¼ 0.03) patients with IR compared to patients without IR. Therefore, within each category of obesity, stratification by IR status proved a useful but divergent indicator of the concentrations of adiponectin and leptin. Adiponectin and the metabolic syndrome OA Mojiminiyi et al
Performance characteristics for the detection of the metabolic syndrome Compared to the other laboratory criteria for the detection of the metabolic syndrome, adiponectin, at cutoff point of 18 ng/ml, had relatively high sensitivity and specificity (Table 4) . Receiver operating characteristic plots for adiponectin, leptin, leptin:adiponectin ratio, HDL-C and TGs are presented in Figure 3 . The ROC analysis demonstrated a significant (Po0.01) difference between the diagnostic efficiency of adiponectin and that of leptin, leptin:adiponectin ratio and TGs for the detection of the metabolic syndrome. The AUCs for the adiponectin, leptin, leptin:adiponectin ratio, HDL-C and TGsROC plots are shown in Table 5 .
Discussion
Our results show that adiponectin and leptin levels show divergent and variable correlations with obesity, IR and the components of the metabolic syndrome. While leptin showed significant positive associations with indices of obesity, IR and CRP, adiponectin showed the opposite trend confirming previous observations on its insulin-sensitizing, anti-inflammatory and antiatherogenic properties. 15, 16 Several potential mechanisms for adiponectin's unique antidiabetic, antiinflammatory and antiatherogenic effects have been described. Adiponectin enhances insulin sensitivity in the liver and reduces hepatic glucose output, stimulates glucose use and fatty acid oxidation in skeletal muscle, inhibits monocyte adhesion and decreases proliferation of migrating smooth muscle cells in the vascular wall where it also increases nitric oxide production in endothelial cells. 17, 18 We have also shown that levels of adiponectin are strongly correlated with insulin sensitivity and low adiponectin was found in patients with IR. This is similar to the finding in Pima Indians 16 where it was shown that high adiponectin levels protects against the impairment of glucose metabolism in obese patients and reduces the risk of developing Type 2 diabetes. With regard to the link between obesity, the metabolic syndrome and diabetes, the relationship is complex and accumulated evidence indicates that obesity is the central feature given that adipokines are involved in insulin action as well as glucose and lipid metabolism. 19, 20 The exact mechanisms of the association between adiponectin, insulin and IR have not been fully elucidated, but some studies have shown that insulin may regulate proteins secreted from fat cells as previously described for leptin. 21, 22 There is also evidence that insulin may have direct effect on adiponectin gene expression and adiponectin concentrations in vitro.
23-25
It is therefore conceivable that the higher levels of insulin in insulin-resistant subjects may downregulate levels of adiponectin as suggested previously. 26, 27 Although we have shown an inverse association between adiponectin and insulin resistance, it is obvious from Figure 2a that there was overlap of adiponectin levels between insulin-sensitive and insulinresistant patients and some of the insulin-sensitive individuals had low adiponectin. Some other studies have reported similar disassociation between adiponectin levels and insulin resistance 28, 29 and the relationship between adiponectin and IR is probably not one of the direct cause and effect in all patients. It is possible that their inverse relationship may be mediated not only by insulin levels but also by other hormones such as catecholamines or androgens, [30] [31] [32] as well as by pro-inflammatory cytokines, 33, 34 and some medications. 31, 35 Our results also depict the prominent role that adipose tissue plays in both insulin resistance and the clinical expression of the metabolic syndrome (Figures 1 and 2 ). The main limitation of this study is the cross-sectional design and longitudinal studies are required to validate the diagnostic usefulness of adiponectin and other adipokines for the detection of subjects at risk of developing the metabolic syndrome. Another potential limitation is the fact that adiponectin circulates in different forms with different states of oligomerization and glycosylation that may have functional consequences. 38, 39 The implications of these are that there is need for standardization of assays used for the estimation of adiponectin. Furthermore, as the expression of the metabolic syndrome may be dependent on several factors that are linked to ethnicity, 40, 41 it would also be necessary to establish the adiponectin cutoff level for the diagnosis of the metabolic syndrome for different populations. Variability in measured adiponectin should not be construed as a disadvantage because other criteria for diagnosis of the metabolic syndrome (e.g. WC, HDL-C, TG) have the same analytical limitations and also show wide variations in different populations. [41] [42] [43] In summary, Type 2 diabetes mellitus represents an ideal paradigm for the study of the interplay between obesity and the multiple factors that confer increased risk of developing the metabolic syndrome and cardiovascular disease. In view of the current controversy on the precise definition, criteria for diagnosis and pathophysiology of the metabolic syndrome, 3, 43, 44 some physicians may have problems with including another criterion for the definition of the metabolic syndrome. However, all sides of the debate acknowledge the need for the early identification and treatment of individuals with clustering of cardiometabolic risk factors and the fact that the presence of abdominal obesity, which is highly correlated with insulin resistance, are necessary for such identification. Adiponectin, which we have shown to be associated with obesity, insulin resistance and inversely associated with the expression of the metabolic syndrome in patients with Type 2 diabetes mellitus, would be a useful adjunct to the current criteria for identification of these patients.
